St. Louis Ranked #4 Nationally Among Top 10 U.S. Biopharma Clusters

The days of biotech businesses and institutions limiting their research and commercial activity to top clusters like Boston/Cambridge, MA, and the San Francisco Bay Area are passing, as the life sciences expand their horizons to regions and states not usually thought of as hotspots for the industry.

“Life science entrepreneurship and new product development is flourishing outside traditional coastal epicenters, creating a dynamic and distributed map of regional hubs across the United States,” wrote John Flavin, founder and CEO of venture capital firm Portal Innovations, and Pat Flavin, John’s brother and Portal’s president, in Biotech’s Future Will Be More Distributed, a guest editorial published December 15, 2025, by Timmerman Report.

Reflecting the strength of its institutions, St. Louis dominates emerging regions in patents, where it leads with 11,049 families, and is a strong second in NIH funding with 1,855 awards totaling $1.186 billion. The region places sixth in VC funding with $134 million (BioSTL), seventh in workforce with 21,376 life-sci jobs (BioSTL), and 10th in lab space (an estimated 3.185 million square feet based on Cortex’s 1.9 million, 39 North’s 1 million, and 285,000 square feet of incubator space (BioSTL + GEN research).